Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients).

"Declarations Conflicts of interestProf Jacob has served as an international advisory board member for Alexion, Alnylam, ArgenX, Immunovant, Janssen, Regeneron and UCB pharmaceuticals, is currently an expert panel member of Myasthenia Gravis consortium for Argenx pharmaceuticals, and has received speaker fees from Terumo BCT and Eisai pharmaceuticals. None of these are relevant to the submitted manuscript. Prof. Mollan reports advisory board membership for Invex Therapeutics and Janssen. She is currently a consultant for Neurodiem and has received speaker fees from Heidelberg Engineering, and Chugai-Roche Ltd. All outside the submitted work. Dr Appleton is supported in part by a National Institute of Health Research (NIHR) Health and Care Research Scholarship. Conflicts of interest Prof Jacob has served as an international advisory board member for Alexion, Alnylam, ArgenX, Immunovant, Janssen, Regeneron and UCB pharmaceuticals, is currently an expert panel member of Myasthenia Gravis consortium for Argenx pharmaceuticals, and has received speaker fees from Terumo BCT and Eisai pharmaceuticals. None of these are relevant to the submitted manuscript. Prof. Mollan reports advisory board membership for Invex Therapeutics and Janssen. She is currently a consultant for Neurodiem and has received speaker fees from Heidelberg Engineering, and Chugai-Roche Ltd. All outside the submitted work. Dr Appleton is supported in part by a National Institute of Health Research (NIHR) Health and Care Research Scholarship."

"Funding None relevant to this study."